Naperiglipron - Eli Lilly and Company
Alternative Names: GLP-1R NPA II - Eli Lilly; LY-3549492Latest Information Update: 30 Jul 2026
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics; Benzimidazoles; Carboxylic acids; Ethers; Fluorocarbons; Obesity therapies; Pyridines; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
Most Recent Events
- 30 Jul 2026 Chemical structure information added
- 16 Jul 2026 Eli Lily and Company completes a phase I trial for Obesity (In volunteers) in USA (PO) (NCT07232732)
- 28 Jun 2026 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(Combination therapy, Treatment-experienced) in Germany (PO)